Profit

April 15, 2026

Pakistan consumer sector profit rises 28% to Rs244 billion in 2025

Pharma profits jump 79% to Rs36 billion, discretionary earnings reach Rs98 billion, staples at Rs110 billion on revenue growth and stable exchange rate

Monitoring Report

Monitoring Report

April 15, 2026

Pakistan consumer sector profit rises 28% to Rs244 billion in 2025

Listed consumer sector companies in Pakistan posted a combined profit of Rs244 billion in 2025, marking a 28% increase compared to the previous year, according to an analysis by Topline Securities.

The study covered consumer staples, pharmaceuticals and discretionary firms with market capitalisation exceeding $100 million in their respective segments.

Net revenues for these companies grew 14% year-on-year, supported by improved macroeconomic conditions and a relatively stable exchange rate.

Pharmaceutical companies recorded the highest growth, with profits rising 79% to Rs36 billion. The increase was attributed to improved gross margins, supported by lower global active pharmaceutical ingredient (API) costs and deregulation of non-essential drug prices.

Discretionary sector companies reported a 35% increase in profits to Rs98 billion. Gross margins in this segment improved to 17.32% in 2025 from 15% in 2024, driven by stable currency conditions, higher automobile sales and the introduction of new product variants.

Consumer staples companies posted profits of Rs110 billion, reflecting a 13% increase over the previous year.

Analysts said the overall growth in the consumer sector reflects improving demand conditions and cost dynamics across key segments.

Share:
Monitoring Report
Monitoring Report

Our monitoring team diligently searches the vast expanse of the web to carefully handpick and distill top-tier business and economic news stories and articles, presenting them to you in a concise and informative manner.

View all articles →

0 Comments

Sort by:
0/2000
Supports: **bold** *italic* [link](url) > quote @mention
Guest comments require moderation

No comments yet. Be the first to join the discussion!